- Home
- SILO vs KZIA Comparison
SILO vs KZIA Comparison
Compare SILO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- KZIA
- Stock Information
- Founded
- SILO 2010
- KZIA 1994
- Country
- SILO United States
- KZIA Australia
- Employees
- SILO N/A
- KZIA 7
- Industry
- SILO Apparel
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- KZIA Health Care
- Exchange
- SILO Nasdaq
- KZIA Nasdaq
- Market Cap
- SILO 8.8M
- KZIA 6.0M
- IPO Year
- SILO N/A
- KZIA 1999
- Fundamental
- Price
- SILO $1.59
- KZIA $1.08
- Analyst Decision
- SILO
- KZIA Strong Buy
- Analyst Count
- SILO 0
- KZIA 2
- Target Price
- SILO N/A
- KZIA $11.50
- AVG Volume (30 Days)
- SILO 598.0K
- KZIA 5.5M
- Earning Date
- SILO 02-18-2025
- KZIA 03-26-2025
- Dividend Yield
- SILO N/A
- KZIA N/A
- EPS Growth
- SILO N/A
- KZIA N/A
- EPS
- SILO N/A
- KZIA N/A
- Revenue
- SILO $72,102.00
- KZIA $1,655,324.00
- Revenue This Year
- SILO $1.86
- KZIA $806.89
- Revenue Next Year
- SILO N/A
- KZIA N/A
- P/E Ratio
- SILO N/A
- KZIA N/A
- Revenue Growth
- SILO N/A
- KZIA 248000.00
- 52 Week Low
- SILO $0.77
- KZIA $1.15
- 52 Week High
- SILO $4.50
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- SILO 52.57
- KZIA 32.04
- Support Level
- SILO $1.56
- KZIA $1.31
- Resistance Level
- SILO $1.89
- KZIA $1.60
- Average True Range (ATR)
- SILO 0.19
- KZIA 0.26
- MACD
- SILO -0.05
- KZIA 0.05
- Stochastic Oscillator
- SILO 27.12
- KZIA 0.64
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.